×
About 53,270 results

Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatr...
https://doi.org/10.1007/s00280-022-04446-y 10.3109/07357909709047587 10.2165/00003088-199631030-00003 10.1517/14740338.4.5.915 10.1038/nrclinonc.2010.82 10.1016/j.trecan.2020.05.007 10.1016/j.ejps.2021.105812 10.1038/nrd4609 10.1007/s40262-013-0040-2 10.1023/A:1013180903805 10.1111/bcp.15131 10.1007/s00280-005-0132-2 10.1200/JCO.2005.02.1295 10.1007/s00280-018-3751-0 10.1007/BF01113502 10.1007/BF00685841 10.1681/ASN.2008030287 10.1007/s40262-015-0277-z 10.1093/bja/aer057 10.1177/0115426507022002240 10.1038/psp.2013.14 10.1002/psp4.12611 10.1097/MOP.0b013e32835c1cbe 10.1007/s40272-014-0113-1 10.1046/j.1365-2125.2002.01581.x 10.1007/s00228-002-0506-x 10.1007/s00280-003-0729-2 10.1016/j.vascn.2003.09.001 10.1158/1078-0432.CCR-05-1541 10.1007/s00280-006-0359-6 10.1007/s00280-004-0942-7 10.1016/j.lungcan.2005.04.003 10.1007/s00280-001-0378-2 10.21037/jtd.2019.08.22 10.1007/s00280-019-04000-3 10.1111/bcp.15131 10.1038/clpt.1981.180 10.1007/BF00614200 10.1007/BF01066319 10.1023/A:1018993501426 10.2133/dmpk.DMPK-12-RG-005 10.1073/pnas.84.21.7735 10.2133/dmpk.21.238 10.1124/mol.111.077099 10.1007/BF02614215 10.1124/dmd.105.005611 10.1124/dmd.114.056929 10.1038/nrg3185 10.1021/mp0600687 10.1007/s00280-005-1025-0 10.1002/bdd.2052 10.1016/S0009-9236(96)90208-8 10.1093/annonc/mdm285 10.2165/00003088-200342010-00003 10.1515/CCLM.2000.127 10.5414/CPP38069 10.1067/mcp.2001.117412 10.1159/000108407 10.1007/s00280-015-2845-1 10.1038/s41598-021-81792-6 10.3233/BD-140386 10.1038/clpt.2012.79 10.1016/j.jpba.2007.12.006 10.1054/bjoc.2000.1203 10.1002/cpt.1954 10.1016/S1470-2045(19)30617-5 10.1177/0300891619888021 10.1111/bcp.12305 10.1200/JCO.2002.02.140 10.1002/psp4.12191 10.1517/17425255.2012.693480 10.1002/psp4.12542 10.1124/dmd.115.065920 10.1016/j.pharmthera.2020.107541
Cancer Chemotherapy and Pharmacology; Hamimed M, Leblond P et. al.

Jun 26th, 2022 - Better understanding of pharmacokinetics of oral vinorelbine (VNR) in children would help predicting drug exposure and, beyond, clinical outcome. Here, we have characterized the population pharmacokinetics of oral VNR and studied the factors likely to explain the variability observed in VNR exposure among young patients. We collected blood samples from 36 patients (mean age 11.6 years) of the O...

Spatio-temporal dynamics of pathogenic variants associated with monogenic disorders rec...
https://doi.org/10.1371/journal.pone.0269628
PloS One; Toncheva D, Marinova M et. al.

Jun 25th, 2022 - Genetic disease burden in ancient communities has barely been evaluated despite an ever expanding body of ancient genomes becoming available. In this study, we inspect 2729 publicly available ancient genomes (100 BP-52000 BP) for the presence of pathogenic variants in 32643 disease-associated loci. We base our subsequent analyses on 19 variants in seven genes-PAH, EDAR, F11, HBB, LRRK2, SLC12A6...

Canine leptospirosis in Canada, test-positive proportion and risk factors (2009 to 2018...
https://doi.org/10.1371/journal.pone.0270313
PloS One; Stull JW, Evason M et. al.

Jun 25th, 2022 - Over the past decade, there has been an apparent increased frequency and widened distribution of canine leptospirosis in Canada, however, this has been minimally investigated. Availability and clinical uptake of Leptospira polymerase chain reaction (PCR)-based testing of dogs in Canada may provide important insight into the epidemiology of this canine and zoonotic infectious disease. Study obje...

Geographic distribution of human leishmaniasis and phlebotomine sand flies in the State...
https://doi.org/10.1186/s13071-022-05353-0 10.1007/s00253-020-10846-y 10.1016/j.jaad.2014.08.051 10.1371/journal.pntd.0008253 10.1590/S0037-86822006000300010 10.1590/S0031-10492011002700001 10.1007/978-3-319-75544-1_2 10.3157/0013-872X(2007)118[351:APOGAS]2.0.CO;2 10.1016/j.jinf.2006.08.004 10.1590/0074-0276130331 10.5430/crcp.v6n1p19 10.1590/S0034-89102007000600007 10.1093/jme/tjaa127 10.1016/j.exppara.2008.03.011 10.1590/S0085-56262010000200014 10.1590/0074-02760140462 10.1371/journal.pone.0099207 10.1016/j.ijpara.2017.04.007 10.1186/s13071-016-1444-2 10.1590/1806-9665-rbent-2020-0074
Parasites & Vectors; Neitzke-Abreu HC, Costa GB et. al.

Jun 25th, 2022 - In the State of Mato Grosso do Sul, Brazil, sand flies and cases of visceral (VL) and cutaneous (CL) leishmaniases have been reported in almost all municipalities. The aim of this study was to analyze the geographic distribution of VL and CL in relation the sand fly species found in the municipalities of Mato Grosso do Sul. We analyzed VL and CL cases from 2001 to 2018 using data from the Notif...

Altered intravenous drug disposition in people living with cystic fibrosis: a meta-anal...
https://doi.org/10.1002/psp4.12832
CPT: Pharmacometrics & Systems Pharmacology; De Sutter PJ, Van Haeverbeke M et. al.

Jun 25th, 2022 - Cystic fibrosis has been linked to altered drug disposition in various studies. However, the magnitude of these changes, influencing factors and underlying mechanisms remain a matter of debate. The primary aim of this work was therefore to quantify changes in drug disposition (top-down) and the pathophysiological parameters known to affect pharmacokinetics (bottom-up). This was done through met...

Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target ...
https://doi.org/10.1038/s41467-022-31340-1 10.1126/science.1164382 10.1007/s00401-007-0243-4 10.1016/j.cell.2015.12.028 10.1016/j.ccr.2009.12.020 10.1073/pnas.1219747110 10.1016/j.cell.2013.09.034 10.1158/2159-8290.CD-20-1474 10.1126/science.aaf2666 10.1016/j.ccell.2017.06.003 10.1126/science.1254257 10.3389/fonc.2020.00494 10.1038/s43018-020-00159-4 10.1186/s40478-021-01151-4 10.1016/j.ccell.2021.05.002 10.1016/j.cell.2019.06.024 10.1016/j.bbamcr.2020.118782 10.1002/advs.202002015 10.1093/brain/awz044 10.1038/s41580-020-0237-9 10.1038/s41568-019-0213-x 10.1038/nature08712 10.1371/journal.pone.0034705 10.1016/j.neo.2014.06.003 10.1039/C7IB00152E 10.15252/embr.201439246 10.1002/bies.200800084 10.1038/ncb2548 10.1039/C4IB00115J 10.1038/embor.2012.149 10.1038/nrm2720 10.1083/jcb.201508047 10.1016/j.ydbio.2011.12.041 10.1038/s41598-019-38625-4 10.1016/j.bbagen.2014.03.020 10.1186/s40170-020-00221-w 10.1016/j.ajpath.2013.06.026 10.1371/journal.pone.0009808 10.1007/s13277-013-1511-7 10.1158/1541-7786.MCR-13-0236 10.3171/2016.6.JNS152797 10.1093/neuonc/noaa006 10.1126/scitranslmed.aac8228 10.1056/NEJMoa1402121 10.1093/neuonc/now247 10.1371/journal.pcbi.1007611 10.1073/pnas.1118633109 10.1146/annurev-genet-120417-031559 10.1016/j.ceb.2010.08.015 10.1186/1741-7015-4-38 10.1158/0008-5472.CAN-06-2322 10.1186/1755-8794-3-51 10.1038/onc.2016.230 10.1021/acs.molpharmaceut.8b00319 10.1073/pnas.1018892108 10.1021/jacs.7b13401 10.1016/j.ijpharm.2011.12.015 10.1016/j.jconrel.2017.02.035 10.1038/nn.4185 10.1038/s41556-019-0443-x 10.1038/ncb2985 10.1038/nature14971 10.2217/imt-2017-0122 10.1109/TPAMI.2016.2572683 10.1016/j.patrec.2017.03.023 10.1038/s41591-019-0715-9 10.18632/oncotarget.11589 10.18632/oncotarget.13295 10.1101/gr.6202607 10.1038/nature11039 10.1073/pnas.1902366116 10.1016/j.ymeth.2016.09.016
Nature Communications; Comba A, Faisal SM et. al.

Jun 25th, 2022 - Intra-tumoral heterogeneity is a hallmark of glioblastoma that challenges treatment efficacy. However, the mechanisms that set up tumor heterogeneity and tumor cell migration remain poorly understood. Herein, we present a comprehensive spatiotemporal study that aligns distinctive intra-tumoral histopathological structures, oncostreams, with dynamic properties and a specific, actionable, spatial...

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT03919071

Jun 24th, 2022 - PRIMARY OBJECTIVE: I. To estimate the event-free survival (EFS) distribution for newly-diagnosed patients with BRAFV600-mutant high-grade glioma (HGG) without H3 K27M mutations excluding anaplastic pleomorphic xanthoastrocytoma (aPXA) and anaplastic ganglioglioma (aGG) treated with radiation therapy followed by a maintenance combination of dabrafenib mesylate (dabrafenib) and trametinib dimethy...

Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1)
https://clinicaltrials.gov/ct2/show/NCT01702922

Jun 24th, 2022 - Background: Parents face numerous stressors when their child is diagnosed with cancer or NF1, each of which can strain a marriage/partnership. Marital/partner relationship dynamics are often not assessed or addressed when providing health care for children with cancer or NF1. Many parents struggle to effectively cope with the changes in parenting roles that frequently accompany treatment of chi...

Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
https://clinicaltrials.gov/ct2/show/NCT03831958

Jun 24th, 2022 - Objective: Cushing Disease (CD) describes the state of hypercortisolemia secondary to cortisol producing pituitary adenomas. The rarity of the disease (2-5 new cases per million, 1 out of 10 in children) and the subtle initial findings result in prolonged undiagnosed hypercortisolemia, that increases the risk for significant complications, including obesity, height deceleration, hyperlipidemia,...

A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy
https://clinicaltrials.gov/ct2/show/NCT03362502

Jun 24th, 2022 - This is a first-in-human/first-in-patient, multi-center, open-label, non-randomized, ascending dose, safety and tolerability study of a single intravenous infusion of PF-06939926 in ambulatory and non-ambulatory subjects with Duchenne muscular dystrophy (DMD). Other objectives include measurement of dystrophin expression and distribution, and assessments of muscle strength, quality, and functio...

Role of Genetic Factors in the Development of Lung Disease
https://clinicaltrials.gov/ct2/show/NCT00001532

Jun 24th, 2022 - This study is designed to evaluate genetic mechanisms of lung disease by surveying polymorphic genes involved in respiratory function and examining gene expression in the lung cells of individuals with pulmonary disease (e.g., alpha 1-antitrypsin deficiency, asthma, chronic obstructive pulmonary disease, cystic fibrosis, sarcoidosis, history of infection, and genetic mutations consistent with l...

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
https://clinicaltrials.gov/ct2/show/NCT04145115

Jun 24th, 2022 - PRIMARY OBJECTIVE: I. To determine whether the combination of ipilimumab and nivolumab increases the tumor response rate assessed by modified Response Assessment in Neuro-Oncology (RANO) Criteria in patients with hypermutated recurrent glioblastoma. SECONDARY OBJECTIVES: I. Estimate the overall survival distribution, median survival, and one-year survival rate of patients with hypermutated, rec...

Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases
https://clinicaltrials.gov/ct2/show/NCT01200953

Jun 24th, 2022 - Since the fall 2001 distribution of letters containing Bacillus anthracis spores via the US postal system, increased attention has been paid to the evaluation and management of bioterrorism-related illness. Similarly, the emergence of Severe Acute Respiratory Syndrome (SARS) in 2003, the Middle East Respiratory Syndrome (MERS) in 2012, Ebola virus disease in both 2013-16 and 2018-20, and, most ...

Study of Dark Adaptation in Age-Related Macular Degeneration
https://clinicaltrials.gov/ct2/show/NCT01352975

Jun 24th, 2022 - Objective: This study is designed to investigate the use of dark adaptation as a functional endpoint for progression of eyes with no to intermediate age-related macular degeneration (AMD). To that aim, correlating structural features (obtained from multimodal imaging) as well as genetic and systemic factors obtained from biospecimens with functional measures (including dark adaptation, visual a...

Efficacy Of Doxycycline & Versus Rifampin In Treatment Of Rhinoscleroma
https://clinicaltrials.gov/ct2/show/NCT05431673

Jun 24th, 2022 - Rhinoscleroma is a chronic granulomatous disease endemic in many eastern countries including Egypt, Its causative agent is a gram-negative bacillus, Klebsiella rhinoscleromatis. Low socioeconomic populations are the most affected.. There are four known stages of the lesion. The first of which the 'Catarrhal stage' with purulent rhinorrhea, then there is the 'Atrophic stage' with a picture simil...

Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leu...
https://clinicaltrials.gov/ct2/show/NCT04269902

Jun 24th, 2022 - PRIMARY OBJECTIVE: I. To evaluate whether early treatment with venetoclax and obinutuzumab (V-O) extends overall survival (OS) compared with delayed treatment with V-O in high-risk (Chronic Lymphocytic Leukemia [CLL] International Prognostic Indicator [CLL-IPI] >= 4 or complex cytogenetics), newly diagnosed asymptomatic CLL/small lymphocytic lymphoma (SLL) patients. SECONDARY OBJECTIVES: I. To ...

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
https://clinicaltrials.gov/ct2/show/NCT05099003

Jun 24th, 2022 - PRIMARY OBJECTIVES: I. To define toxicities and estimate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of selinexor administered as an oral formulation in combination with standard of care radiation therapy (RT), to pediatric patients with newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG). (Dose-finding phase/phase I) II. To estimate the e...

Implementation and acceptance of government-sponsored malaria control interventions in ...
https://doi.org/10.1186/s12936-022-04223-5 10.1186/s12936-021-03600-w 10.1186/s12936-020-03402-6 10.4103/0972-9062.257773 10.1002/14651858.CD006657.pub2 10.1038/s41467-018-07357-w 10.1111/tmi.12522 10.1186/1475-2875-9-263 10.1186/s12936-021-03639-9 10.1016/j.jiph.2015.10.005 10.1590/S0074-02762008005000009 10.1007/978-94-007-7055-3 10.4103/0972-9062.257777 10.1186/s12936-021-03679-1 10.1002/14651858.CD012688.pub2 10.1257/aer.104.7.1909 10.12688/wellcomeopenres.12051.1 10.1186/s12936-019-2666-5 10.4269/ajtmh.18-0730 10.1186/s12936-019-2800-4 10.1186/s41182-019-0138-9 10.4269/ajtmh.15-0259 10.1186/s12936-017-2117-0 10.1080/20477724.2020.1776920 10.1186/s12936-021-03837-5 10.1016/j.actatropica.2009.07.013 10.1186/1475-2875-12-39 10.1186/s12936-021-03811-1 10.1186/s12936-020-03475-3 10.4269/ajtmh.20-0189 10.4269/ajtmh.19-0660 10.1371/journal.pone.0252690 10.1186/1475-2875-13-82 10.1186/s12936-018-2314-5 10.1186/s12936-021-03724-z 10.1186/s12936-015-0727-y 10.1186/s12936-019-3088-0 10.1186/s13104-018-3697-7 10.1186/1475-2875-6-48 10.1186/s12936-021-03607-3 10.1186/s12936-018-2563-3 10.1186/s12936-021-03982-x 10.1371/journal.pone.0243303 10.1186/s12936-020-03469-1 10.1186/s12936-016-1262-1 10.1186/s12936-018-2610-0 10.1186/1475-2875-13-344 10.1186/s12936-020-03260-2 10.4103/0971-5916.176628 10.5455/ijmsph.2015.16092014214 10.1186/s12936-020-3102-6 10.1186/1475-2875-11-220 10.1186/s12889-020-08505-y 10.1186/s13071-017-2548-z 10.1186/s12936-019-2653-x 10.1186/s12936-020-03517-w 10.11604/pamj.2015.20.27.4721 10.1186/s12936-020-03534-9 10.17795/jhealthscope-8344 10.11604/pamj.2019.33.84.13212 10.1186/s12936-019-2811-1 10.1093/infdis/jiaa582 10.1186/s12936-021-03611-7 10.1016/S0140-6736(14)61007-2 10.4103/ijmr.IJMR_1175_18 10.1007/s13312-020-1888-5
Malaria Journal; Passah M, Nengnong CB et. al.

Jun 24th, 2022 - India has made considerable progress in malaria reduction over the past two decades, with government-sponsored indoor residual spraying (IRS) and insecticide-treated bed net (ITN) or long-lasting insecticidal nets (LLIN) distribution being the main vector-related prevention efforts. Few investigations have used non-participant observational methods to assess malaria control measures while they ...

Antiviral efficacy of selective estrogen receptor modulators against SARS-CoV-2 infecti...
https://doi.org/10.1002/jmv.27951
Journal of Medical Virology; Miao G, Peng H et. al.

Jun 24th, 2022 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh member of the coronavirus family that can infect humans. Recently, more contagious and pathogenic variants of SARS-CoV-2 have been continuously emerging. Clinical candidates with high efficacy and ready availability are still in urgent need. To identify potent anti-SARS-CoV-2 repurposing drugs, we evaluated the antivira...

Geographical distribution and genetic diversity of Plasmodium vivax reticulocyte bindin...
https://doi.org/10.1371/journal.pntd.0010492
PLoS Neglected Tropical Diseases; Park JH, Kim MH et. al.

Jun 24th, 2022 - Plasmodium vivax is the most widespread cause of human malaria. Recent reports of drug resistant vivax malaria and the challenge of eradicating the dormant liver forms increase the importance of vaccine development against this relapsing disease. P. vivax reticulocyte binding protein 1a (PvRBP1a) is a potential vaccine candidate, which is involved in red cell tropism, a crucial step in the mero...